Cost-Utility Analysis of Adjuvant Trastuzumab Therapy for HER2-positive Early-Stage Breast Cancer in the Philippines

BMC Health Services Research - United Kingdom
doi 10.1186/s12913-019-4715-8
Full Text
Abstract

Available in full text

Categories
Health Policy
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Trastuzumab as Adjuvant Treatment for Early Stage HER2-positive Breast Cancer — A 10 Year History

Nowotwory
Cancer ResearchOncology
2017English

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

New England Journal of Medicine
Medicine
2005English

Pcn74 - A Budget-Impact Analysis of Adjuvant Pertuzumab and Trastuzumab in Early Her2-Positive Breast Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pcn181 - Cost-Utility Analysis of Adjuvant Pertuzumab-Based Regimen in Women With Her2-Positive Breast Cancer in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2016English

Optimal Treatment of Early Stage HER2-positive Breast Cancer

Cancer
Cancer ResearchOncology
2018English

Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2019English

Cost-Utility Analysis of Adjuvant Therapies for Breast Cancer in Iran

International Journal of Technology Assessment in Health Care
Health Policy
2012English

Pcn20 - Contribution of Trastuzumab to the Prognostic Improvement of Her2-Positive Early Breast Cancer in Spain

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy